Taroh Satoh

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

An anonymous communication technique using dummies for location-based services

Hidetoshi Kido, Y. Yanagisawa, Taroh Satoh · 2005 · 688 citations

Computing, Computer Science, Information Technology +16

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 670 citations

Medicine, Oncology, Pharmacology +17

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung et al. · Journal of Clinical Oncology · 2014 · 624 citations · Full text

Medicine, Oncology, Pharmacology +15